What are the benefits and recommended dosing of N‑acetylcysteine (NAC) for treating ischemic hepatitis (shock liver) secondary to cardiogenic shock?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

NAC in Shock Liver from Cardiogenic Shock

N-acetylcysteine (NAC) should be initiated in patients with ischemic hepatitis (shock liver) secondary to cardiogenic shock, as it improves transplant-free survival and reduces mortality in non-acetaminophen acute liver failure, with the standard dosing being 150 mg/kg IV over 1 hour, followed by 12.5 mg/kg/hr for 4 hours, then 6.25 mg/kg/hr for 67 hours (total 72 hours). 1

Evidence-Based Rationale

The 2020 intensive care guidelines provide the strongest recommendation for this clinical scenario. While FDA labeling restricts NAC to acetaminophen toxicity 2, guideline evidence supersedes this limitation for shock liver. The 2020 guidelines explicitly recommend NAC for acute liver failure "whatever the aetiology" (GRADE 2+), including ischemic hepatitis from cardiogenic shock 1.

Key Benefits in Non-Acetaminophen Liver Failure

Meta-analysis data demonstrates:

  • Improved overall survival: 76% vs 59% (OR 2.30,95% CI 1.54-3.45) 1
  • Enhanced transplant-free survival: 64% vs 26% (OR 4.81,95% CI 3.22-7.18) 1
  • Better post-transplant survival: 85.7% vs 71.4% (OR 2.44,95% CI 1.11-5.37) 1

Mechanisms Specific to Cardiogenic Shock

NAC provides multiple benefits in the cardiogenic shock setting:

  • Increases hepatic blood flow by improving cardiac output (5.0 to 5.7 L/min/m²) and absolute liver blood flow index (2.7 to 3.3 L/min/m²) 3
  • Reduces hepatosplanchnic hypoxia (decreased arterial-gastric mucosal CO₂ gradient) 3
  • Prevents acute kidney injury (OR 0.34,95% CI 0.15-0.75), a common comorbidity 4
  • Reduces deaths from liver failure (subdistribution hazard ratio 0.33,95% CI 0.11-0.97) 4

Recommended Dosing Protocol

Standard 72-hour IV regimen 1, 4:

  1. Loading dose: 150 mg/kg IV over 1 hour
  2. Second phase: 12.5 mg/kg/hr for 4 hours
  3. Maintenance: 6.25 mg/kg/hr for 67 hours

This totals 72 hours of continuous therapy, which was the protocol used in the studies demonstrating mortality benefit.

Clinical Implementation Algorithm

When to Initiate NAC:

  • Immediately upon recognition of ischemic hepatitis in cardiogenic shock
  • Do not wait for transaminase peaks
  • Early initiation is critical—benefit is greatest in patients with grades I-II encephalopathy 1

Diagnostic Criteria for Ischemic Hepatitis in Cardiogenic Shock:

Recent evidence shows the septic shock definition (20-fold transaminase elevation) does not apply to cardiogenic shock. Cardiogenic shock-specific hypoxic hepatitis (C-HH) is defined as 5:

  • ASAT ≥1.34-fold increase from baseline
  • ALAT ≥1.51-fold increase from baseline
  • Occurs in 36% of cardiogenic shock patients
  • Associated with doubled mortality risk (OR 2.36)

Monitoring Requirements:

  • AST, ALT, bilirubin, INR every 12-24 hours
  • Creatinine and BUN (NAC reduces AKI risk) 4
  • Cardiac index and hepatic perfusion parameters if available
  • Watch for encephalopathy progression

Important Caveats

Adverse effects are minimal but include:

  • Nausea, vomiting, diarrhea (common)
  • Skin rash (<5%)
  • Transient bronchospasm (1-2%)
  • Anaphylactoid reactions (rare with slower infusion rates)

Timing considerations:

  • Maximum benefit occurs when started early, before progression to grade III-IV encephalopathy 1
  • Even late initiation (>8 hours) does not worsen outcomes and should not be withheld 2

Guideline divergence: The 2017 AGA guidelines recommend NAC only in clinical trials for non-acetaminophen ALF 6, but this is superseded by the more recent 2020 intensive care guidelines that provide a positive recommendation based on newer meta-analyses 1.

Clinical Context

Ischemic hepatitis from cardiogenic shock carries mortality up to 60% 7, 8. NAC's mechanisms—improving hepatic blood flow, reducing oxidative stress, and preventing reperfusion injury—directly address the pathophysiology of shock liver 3, 7. The drug is inexpensive, widely available, and has minimal toxicity, making it appropriate for routine use in this high-mortality condition.

The evidence strongly supports NAC use in shock liver from cardiogenic shock, with the standard 72-hour IV protocol initiated as soon as ischemic hepatitis is recognized.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.